ATF3 rSNPs, transcriptional factor binding sites and human etiology


Three rSNPs (rs3125289, rs1877474 and rs11119982) in one intron of the activating transcription factor 3 (ATF3) gene have been significantly associated with the human etiology of hypospadias and may be associated with human disease. These rSNP alleles alter the DNA landscape for potential transcriptional factors (TFs) to attach resulting in changes in transcriptional factor binding sites (TFBS). These TFBS changes are examined with respect to the human etiology of hypospadias which has been found to be significantly associated with the rSNPs.

Share and Cite:

Buroker, N. (2013) ATF3 rSNPs, transcriptional factor binding sites and human etiology. Open Journal of Genetics, 3, 253-261. doi: 10.4236/ojgen.2013.34028.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Chen, B.P., Liang, G., Whelan, J. and Hai, T. (1994) ATF3 and ATF3 delta Zip. Transcriptional repression versus activation by alternatively spliced isoforms. The Journal of Biological Chemistry, 269, 15819-15826.
[2] Hai, T. and Hartman, M.G. (2001) The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: Activating transcription factor proteins and homeostasis. Gene, 273, 1-11.
[3] Thompson, M.R., Xu, D. and Williams, B.R. (2009) ATF3 transcription factor and its emerging roles in immunity and cancer. Journal of Molecular Medicine, 87, 1053-1060.
[4] Hai, T., Wolford, C.C. and Chang, Y.S. (2010) ATF3, a hub of the cellular adaptive-response network, in the pathogenesis of diseases: is modulation of inflammation a unifying component? Gene Expression, 15, 1-11.
[5] Liu, B., Agras, K., Willingham, E., Vilela, M.L. and Baskin, L.S. (2006) Activating transcription factor 3 is estrogen-responsive in utero and upregulated during sexual differentiation. Hormone Research, 65, 217-222.
[6] Beleza-Meireles, A., Tohonen, V., Soderhall, C., Schwentner, C., Radmayr, C., Kockum, I. and Nordenskjold, A. (2008) Activating transcription factor 3: A hormone responsive gene in the etiology of hypospadias. European Journal of Endocrinology, 158, 729-739.
[7] Knight, J.C. (2003) Functional implications of genetic variation in non-coding DNA for disease susceptibility and gene regulation. Clinical Science, 104, 493-501.
[8] Knight, J.C. (2005) Regulatory polymorphisms underlying complex disease traits. Journal of Molecular Medicine, 83, 97-109.
[9] Wang, X., Tomso, D.J., Liu, X. and Bell, D.A. (2005) Single nucleotide polymorphism in transcriptional regulatory regions and expression of environmentally responsive genes. Toxicology and Applied Pharmacology, 207, 84-90.
[10] Wang, X., Tomso, D.J., Chorley, B.N., Cho, H.Y., Cheung, V.G., Kleeberger, S.R. and Bell, D.A. (2007) Identification of polymorphic antioxidant response elements in the human genome. Human Molecular Genetics, 16, 1188-1200.
[11] Claessens, F., Verrijdt, G., Schoenmakers, E., Haelens, A., Peeters, B., Verhoeven, G. and Rombauts, W. (2001) Selective DNA binding by the androgen receptor as a mechanism for hormone-specific gene regulation. The Journal of Steroid Biochemistry and Molecular Biology, 76, 23-30.
[12] Hsu, M.H., Savas, U., Griffin, K.J. and Johnson, E.F. (2007) Regulation of human cytochrome P450 4F2 expression by sterol regulatory element-binding protein and lovastatin. The Journal of Biological Chemistry, 282, 5225-5236.
[13] Takai, H., Araki, S., Mezawa, M., Kim, D.S., Li, X., Yang, L., Li, Z., Wang, Z., Nakayama, Y. and Ogata, Y. (2008) AP1 binding site is another target of FGF2 regulation of bone sialoprotein gene transcription. Gene, 410, 97-104.
[14] Buroker, N.E., Huang, J.Y., Barboza, J., Ledee, D.R., Eastman, R.J., Jr., Reinecke, H., Ning, X.H., Bassuk, J.A. and Portman, M.A. (2012) The adaptor-related protein complex 2, alpha 2 subunit (AP2alpha2) gene is a peroxisome proliferator-activated receptor cardiac target gene. The Protein Journal, 31, 75-83.
[15] Huang, C.N., Huang, S.P., Pao, J.B., Hour, T.C., Chang, T.Y., Lan, Y.H., Lu, T.L., Lee, H.Z., Juang, S.H., Wu, P.P., Huang, C.Y., Hsieh, C.J. and Bao, B.Y. (2012) Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy. Journal of Internal Medicine, 271, 499-509.
[16] Huang, C.N., Huang, S.P., Pao, J.B., Chang, T.Y., Lan, Y.H., Lu, T.L., Lee, H.Z., Juang, S.H., Wu, P.P., Pu, Y.S., Hsieh, C.J. and Bao, B.Y. (2012) Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy. Annals of Oncology, 23, 707-713.
[17] Yu, B., Lin, H., Yang, L., Chen, K., Luo, H., Liu, J., Gao, X., Xia, X. and Huang, Z. (2012) Genetic variation in the Nrf2 promoter associates with defective spermatogenesis in humans. Journal of Molecular Medicine.
[18] Wu, J., Richards, M.H., Huang, J., Al-Harthi, L., Xu, X., Lin, R., Xie, F., Gibson, A.W., Edberg, J.C. and Kimberly, R.P. (2011) Human FasL gene is a target of betacatenin/T-cell factor pathway and complex FasL haplotypes alter promoter functions. PLoS One, 6, e26143.
[19] Alam, M., Pravica, V., Fryer, A.A., Hawkins, C.P. and Hutchinson, I.V. (2005) Novel polymorphism in the promoter region of the human nerve growth-factor gene. International Journal of Immunogenetics, 32, 379-382.
[20] Bryne, J.C., Valen, E., Tang, M.H., Marstrand, T., Winther, O., da Piedade, I., Krogh, A., Lenhard, B. and Sandelin, A. (2008) JASPAR, the open access database of transcription factor-binding profiles: New content and tools in the 2008 update. Nucleic Acids Research, 36D, 102-106.
[21] Sandelin, A., Alkema, W., Engstrom, P., Wasserman, W.W. and Lenhard, B. (2004) JASPAR: An open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Research, 32D, 91-94.
[22] Sandelin, A., Wasserman, W.W. and Lenhard, B. (2004) ConSite: web-based prediction of regulatory elements using cross-species comparison. Nucleic Acids Research, 32, W249-252.
[23] Pennisi, E. (2011) The Biology of Genomes. Disease risk links to gene regulation. Science, 332, 1031.
[24] Kumar, V., Wijmenga, C. and Withoff, S. (2012) From genome-wide association studies to disease mechanisms: Celiac disease as a model for autoimmune diseases. Seminars in Immunopathology, 34, 567-580.
[25] Hindorff, L.A., Sethupathy, P., Junkins, H.A., Ramos, E.M., Mehta, J.P., Collins, F.S. and Manolio, T.A. (2009) Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proceedings of the National Academy of Sciences, 106, 9362-9367.
[26] Kumar, V., Westra, H.J., Karjalainen, J., Zhernakova, D.V., Esko, T., Hrdlickova, B., Almeida, R., Zhernakova, A., Reinmaa, E., Vosa, U., Hofker, M.H., Fehrmann, R.S., Fu, J., Withoff, S., Metspalu, A., Franke, L. and Wijmenga, C. (2013) Human disease-associated genetic variation impacts large intergenic non-coding RNA expression. PLoS Genetics, 9, e1003201.
[27] Chorley, B.N., Wang, X., Campbell, M.R., Pittman, G.S., Noureddine, M.A. and Bell, D.A. (2008) Discovery and verification of functional single nucleotide polymerphisms in regulatory genomic regions: current and developing technologies. Mutation Research, 659, 147-157.
[28] Prokunina, L. and Alarcon-Riquelme, M.E. (2004) Regulatory SNPs in complex diseases: Their identification and functional validation. Expert Reviews in Molecular Medicine, 6, 1-15.
[29] Buckland, P.R. (2006) The importance and identification of regulatory polymorphisms and their mechanisms of action. Biochimica et Biophysica Acta, 1762, 17-28.
[30] Sadee, W., Wang, D., Papp, A.C., Pinsonneault, J.K., Smith, R.M., Moyer, R.A. and Johnson, A.D. (2011) Pharmacogenomics of the RNA world: Structural RNA polymorphisms in drug therapy. Clinical Pharmacology & Therapeutics, 89, 355-365.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.